

<b>Gender M</b>	51/64 (80%)
<b>Age at diagnosis, median (range)</b>	60 (42-78)
<b>Cytogenetic at time first detection of 2p+</b>	
..Karyotyping (n=53*)	
Normal karyotype	7 (13%)
Complex karyotype ( $\geq 3$ abnormalities)	28 (53%)
Highly complex karyotype ( $\geq 5$ abnormalities)	14 (26%)
..Recurrent 2p gain identified by karyotyping (n=17**)	
.....t(2;18)	5 (29%)
.....dup(2p)	4 (24%)
.....t(2;20)	2 (12%)
.....t(2;22)	2 (12%)
..FISH/SNP array (n=64)	
del(13q)	39 (61%)
del(11q)	34 (53%)
del(17p)	16 (25%)
tri12	2 (3%)
Unmutated <i>IGHV</i> (n=56x)	50 (89%)
<b>Description of the population at last follow-up</b>	
.....Time from diagnosis to first treatment, median [95%CI] (n=62x)	16 m [8-25]
.....Number of lines of treatment, median (range) (n=62x)	2 (0-8)
.....Deaths (n=64x)	28 (44%)
.....Overall survival, median [95%CI] (n=60x)	124m [114-not reached]
.....Follow-up from diagnosis, median (range) (n=60x)	79 m (0-317)
<b>Patients not treated when 2p+ was first detected (n=41x)</b>	
..Binet stage at cytogenetic study (n=36x)	
.....A	4 (11%)
.....B	27 (75%)
.....C	5 (14%)
..Karyotyping (n=35*)	
Normal karyotype	5 (14%)
Complex karyotype ( $\geq 3$ abnormalities)	17 (49%)
Highly complex karyotype ( $\geq 5$ abnormalities)	9 (26%)
..FISH/SNP array (n=41)	
.....del(13q)	26 (63%)
.....del(11q)	24 (58%)
.....del(17p)	8 (19%)
.....tri12	1 (2%)
..Unmutated <i>IGHV</i> (n=36x)	32 (89%)
<b>Patients treated when 2p+ was first detected (n=22x)</b>	
..Number of previous lines, median (range)	3 (2-8)
.....chlorambucil	3
.....F/FC	4
.....FCR	14
.....alemtuzumab	5
.....bendamustine, ofatumumab, methylprednisolone	1
.....BR	1
.....idelalisib-R	1
.....Other	4

**SUPPLEMENTAL TABLE S1.** Clinical and Cytogenetic data of 64 2p+ CLL

\*Successful karyotyping

\*\*The 2p gain was clearly identified by karyotyping in 17 patients. Some 2p abnormalities were recurrent.

x Patients with available data

m=months, F: fludarabine, C: cyclophosphamide, B: bendamustine, R: rituximab